Recombinant Human BCHE Protein (C-6His)

Name: Recombinant Human BCHE Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-1357NP
Availability: InStock

BL-1357NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Butyrylcholine Esterase is produced by our Mammalian expression system and the target gene encoding Glu29-Leu602 is expressed with a 6His tag at the C-terminus.
Accession	P06276
Synonym	Cholinesterase; Acylcholine Acylhydrolase; Butyrylcholine Esterase; Choline Esterase II; Pseudocholinesterase; BCHE; CHE1
Gene Background	Butyrylcholine Esterase (BCHE) is a secreted protein that belongs to the type-B carboxylesterase/lipase family. BCHE is a major acetylcholine hydrolyzing enzyme in the circulation. It is detected in blood plasma and present in most cells except erythrocytes. BCHE is an esterase with broad substrate specificity. BCHE can contribute to the inactivation of the neurotransmitter acetylcholine. BCHE can degrade a large number of neurotoxic organophosphate esters. Thus, it plays important pharmacological and toxicological roles and is thought to be involved in the pathological progression. Defects in BCHE are the cause of butyrylcholinesterase deficiency (BChE deficiency) which is a metabolic disorder characterized by prolonged apnoea after the use of certain anesthetic drugs, including the muscle relaxants succinylcholine and other ester local anesthetics.
Molecular Mass	66.12 KDa
Apmol Mass	90 KDa, reducing conditions
Formulation	Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 7.5.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution
Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Subcellular Location	Secreted.
Protein Families	Type-B carboxylesterase/lipase family
Database References	HGNC: 983 OMIM: 177400 KEGG: hsa:590 STRING: 9606.ENSP00000264381 UniGene: PMID: 29358722 This study validated preoperative serum BChE levels as an independent prognostic factor for urinary tract urothelial carcinoma after radical nephroureterectomy. PMID: 29177431 we present and examine means of manipulating brain BChE levels by viral gene transfer, either regionally or globally, to modulate ghrelin signaling for long-term therapeutic purposes and to set the stage for exploring the neurophysiological impact of such an intervention. PMID: 28698452 The BChE-K polymorphisms are associated with deleterious changes in cognitive decline in MCI patients treated with donepezil for 3 years. PMID: 27911294 BCHE-K* positive subjects (and APOE-epsilon4) display an earlier age of onset of Alzheimer's Disease and an accelerated cognitive decline. PMID: 27567841 Discovery of potent carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase enzymes inhibitors: The new amides and thiazolidine-4-ones synthesized on an acetophenone base.() PMID: 28544359 HuBChE sequesters OP nerve agent in the bloodstream preventing the nerve agent from reaching critical target organ systems. HuBChE was effective when used as both a pre-treatment and as a post-exposure therapy. PMID: 28225154 Significance of BChE Genetic Variants to Risk of Toxicity from Cholinesterase Inhibitors (review) PMID: 27551784 Age, sex or smoking status did not influence butyrylcholinesterase activity in a healthy population. PMID: 28465191 Mutations in the butyrylcholinesterase gene were associated with prolonged effect of succinylcholine or mivacurium. PMID: 27031121 prolonged apnea after suxamethonium came about as a result of butyrylcholinesterase deficiency or mutation or acquired conditions leading to a decrease in the plasma cholinesterase activity PMID: 26439437 the molecular mechanisms by which point mutations may lead to silent BChE variant or alter catalytic activity, is reported. PMID: 27062896 BChE expression might be regulated by alpha-linolenic acid in HepG2 cells. PMID: 27106529 Nine out of 18 (50%) individuals with butyrylcholinesterase activity below 2000 U/L had a mutation in 5'UTR (32G/A), intron 2 (c.1518-121T/C) or exon 4 (c.1699G/A; the K variant mutation). PMID: 27109752 No significant difference in BChE levels of healthy pregnant women and high-risk pregnant women who had undergone a cesarean section under general anesthesia. PMID: 26955768 Association between polymorphisms of BCHE and vitiligo in a two-step genetic association study. Upon confirmation of genetic association, the effect was investigated by a genotype-phenotype correlation experiment. PMID: 26189613 Low serum Butyrylcholinesterase levels are associated with recurrence in prostate cancer. PMID: 26223693 BCHE-K is associated with a reduced risk for Alzheimer disease and Lewy body dementia whereas APOEvarepsilon4 is associated with more rapid cognitive decline. PMID: 26757188 Low BChE activity as a predictor of mortality in acute myocardial infarction might be related to its association with poor cardiac function. PMID: 27468571 rs1803274 polymorphism of the BCHE gene represents a risk factor for in-stent restenosis after percutaneous coronary intervention. PMID: 26497592 Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PMID: 25835709 BChE is a strong predictor for cardiac mortality specifically in younger patients with acute coronary syndrome aged between 45 and 64 years. PMID: 25933219 High resolution melting analysis for the butyrylcholinesterase atypical variant genotyping is a simple, rapid, sensitive and low cost method PMID: 25336127 There is a link between systemic inflammatory markers, oxidative stress, the PON192rs662-Q allele and BuChE-non-UU-phenotype and their corresponding enzymatic activity which may be considered as a risk factor for the severity of rheumatoid arthritis. PMID: 25179377 There is a significant decrease in serum ChE activity after severe trauma PMID: 25471831 This study proves that the p.Ala34Val BChE variant determines the "silent" phenotype (unable to hydrolyze succinylcholine and mivacurium). PMID: 25264279 Data indicate that butyrylcholinesterase (BChE) was significantly associated with overall survival (OS). PMID: 24951323 analysis of the T920C mutation allele frequency in butyrylcholinesterase gene in an Indian population PMID: 25447891 Plasma arylesterase activity is positively associated with plasma ChE specific activity in a nested case-control study. PMID: 24473115 BChE-K carriers are protected from the pathological detriments of Alzheimer's disease that affect cortical thickness. PMID: 24479631 results confirm the association of APOE with Abeta deposition and represent the largest known effect of BCHE on an AD-related phenotype. PMID: 23419831 Results indicate that BuChE non-UU phenotype and PON 55M allele are significant risk factors for systemic lupus erythematosus. PMID: 24399815 Our findings suggest that the AA genotype of rs1803274 is a risk factor for crack cocaine use, which is more addictive than powder cocaine use. PMID: 24312228 We report the case of a 65-year-old patient who was diagnosed with butyrylcholinesterase resulting in prolonged paralysis and extended mechanical ventilation PMID: 24446003 Two mutants of human BCHE can effectively eliminate (-)-cocaine, cocaethylene and norcocaine in simplified kinetic models of cocaine abuse and overdose associated with the concurrent use of cocaine and alcohol. PMID: 24870023 BChE activity might be involved in the pathogenesis of preeclampsia through influence on lipid and lipoprotein metabolism and oxidative stress. PMID: 23650977 The present data are still inconclusive with respect to a possible contribution of common genetic variants in BCHE to the pathogenesis of attention-deficit/hyperactivity syndrome. PMID: 24041656 CocH3 (BCHE mutant) with an identical concentration with that of the endogenous BChE in human plasma can effectively eliminate both cocaine and norcocaine in a simplified kinetic model of cocaine abuse. PMID: 24125115 BCHE 1914G allele showed higher frequency in the obese group. Carriers of 1914G BCHE allele showed lower mean BChE activity.BCHE 1914G allele is influencing physiological mechanisms related to obesity. PMID: 24001779 Data indicate that high AChE affinity of the compounds was achieved by optimizing different substituents on the pyridazinone ring, without sacrificing the AChE/BuChE selectivity profile. PMID: 23466605 Water in the active site gorge of the D70G mutant is more easily depleted than that in wild-type BChE. PMID: 23782236 These findings show that BCHE can hydrolyze 2-Arachidonoylglycerol which may be evidence of a more specific role for BCHE in endocannabinoid regulation. PMID: 23689009 This review examines the roles of gender and BuChE genotype in the phenotypic expression of Alzheimer disease[review] PMID: 22402324 Elevated levels of BuChE observed in active multiple sclerosis (MS) lesions could be related to the decompaction of myelin characteristic of the disorder. PMID: 22778864 [review] Butyrylcholinesterase has diverged both structurally and in terms of tissue and cellular expression patterns from acetylcholinesterase. PMID: 22750491 aspirin is hydrolyzed in plasma by two enzymes, BChE and a new extracellular form of platelet-activating factor acetylhydrolase, PAFAH1b2. PMID: 23508960 characterized the catalytic activities of wild-type BChE and the A199S/F227A/S287G/A328 W/Y332G mutant against both (+)- and (-)-cocaine at the same time under the same experimental conditions PMID: 22917637 verify amplification and/or deletion in the ACHE, BCHE, EPHB4 and MME genes in 32 samples of sporadic breast cancer PMID: 23063927 performed molecular dynamics simulation to probe the structural stability of Indian variant (L307P) in comparison with wild and other BChE variants (D70G, E497V, V142M) having differential esterase activity PMID: 23123771 Alkylating molecules were synthesized and the crystal structures they form with soman-aged butyrylcholinesterase were solved. PMID: 22922115

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.